Yet, it has also made it difficult for some patients to get their prescriptions filled.
The GLP-1 shortage challenges are exacerbated by a lack of accurate, up-to-date, and accessible GLP-1 supply information.
Patients deserve better, said Ro co-founder and CEO Zachariah Reitano in a press release.
Zepbound and Wegovy are in shortage, according to the FDA.Image: Reuters Photographer (Reuters)
The interactive tool uses Ros nationwide supply data, user-generated reports, and the latest information from the FDA.
Eli Lilly, the maker of Zepbound and Mounjaro, is developing a similar tool.
This article originally appeared onQuartz.
News from the future, delivered to your present.
